Antirheumatic drugs and the risk of tuberculosis

Clinical Infectious Diseases

Volumn 43, Issue 6, 2006, Pages 717-722

  Brassard, Paul ^a,b   Kezouh, Abbas ^b   Suissa, Samy ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TREATMENT OUTCOME; TUBERCULOSIS;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; SIALOGLYCOPROTEINS; TUBERCULOSIS;

EID: 33748310559     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/506935     Document Type: Article

References (27)

1. Bouza E, Moya JG, Munoz P. Infections in systemic lupus erythematosus and rheumatoid arthritis. Infect Dis Clin North Am 2001; 15:335-61.
2. Carmona L, Hernandez-Garcia C, Vadillo C, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003; 30:1436-9.
3. Kim HA, Yoo CD, Baek HJ, et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol 1998; 16:9-13.
4. Mohan AK, Cote TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004; 39:295-9.
5. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-104.
6. Kavanaugh A, Cohen S, Cush JJ. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis. J Rheumatol 2004; 31:1881-4.
7. Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Strom BL, ed. Pharmacoepidemiology, New York: John Wiley & Sons, Ltd., 2000:785-805.
8. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161:S221-47.
9. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545-50.
10. Bieber J, Kavanaugh A. Cigarette smoking, TB, and TNF inhibitors. Ann Rheum Dis 2003; 62:1118-9.
11. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005; 52:1986-92.
12. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50:372-9.
13. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261-5.
14. Hyrich KL. Assessing the safety of biologic therapies in rheumatoid arthritis: the challenges of study design. J Rheumatol Suppl 2005; 72:48-50.
15. Bieber J, Kavanaugh A. Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments. Rheum Dis Clin North Am 2004; 30:257-70.
16. Ehlers S. Why does tumor necrosis factor targeted therapy reactivate tuberculosis? J Rheumatol Suppl 2005; 74:35-9.
17. Imperato AK, Smiles S, Abramson SB. Long-term risks associated with biologic response modifiers used in rheumatic diseases. Curr Opin Rheumatol 2004; 16:199-205.
18. Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994; 47:731-7.
19. Wolfe F, Flowers N, Burke TA, Arguelles LM, Pettitt D. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 2002; 29:1015-22.
20. Schneeweiss S, Glynn RJ, Tsai EH, Avorn J, Solomon DH. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology 2005; 16:17-24.
21. Gardam M, Iverson K. Rheumatoid arthritis and tuberculosis: time to take notice. J Rheumatol 2003; 30:1397-9.
22. Centers for Disease Control and Prevention. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha-California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004; 53:683-6.
23. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005; 60:800-5.
24. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3:148-55.
25. Fleischmann RM. Addressing the safety of anakinra in patients with rheumatoid arthritis, Rheumatology (Oxford) 2003; 42(Suppl 2):ii29-35.
26. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis 2004; 63(Suppl 2):ii2-ii12.
27. van Vollenhoven RF, Klareskog L. The treatment of rheumatoid arthritis: getting better all the time? Arthritis Rheum 2005; 52:991-4.